619P Maintenance versus discontinuation of androgen deprivation therapy during docetaxel administration with a continuous or an intermittent schedule in metastatic, castration resistant, prostate cancer patients: A multicenter randomized phase III study of the Piemonte Oncology Network

Androgen Deprivation ◽

Phase Iii ◽

Intermittent Schedule ◽

Castration Resistant ◽

Phase Iii Study

Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network

European Journal of Cancer ◽

10.1016/j.ejca.2021.06.034 ◽

2021 ◽

Vol 155 ◽

pp. 127-135

Author(s):

Susanna Bianchi ◽

Alessandra Mosca ◽

Alberto Dalla Volta ◽

Veronica Prati ◽

Cinzia Ortega ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation ◽

Phase Iii ◽

Castration Resistant ◽

Phase Iii Study

How should we treat castration-resistant prostate cancer patients who have received androgen deprivation therapy (ADT) plus docetaxel upfront for hormone-sensitive diseae? Mature analysis of the GETUG-AFU 15 phase III trial

Annals of Oncology ◽

10.1093/annonc/mdw372.45 ◽

2016 ◽

Vol 27 ◽

pp. vi259 ◽

Cited By ~ 1

Author(s):

P. Lavaud ◽

G. Gravis ◽

C. Legoupil ◽

S. Foulon ◽

F. Joly ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation ◽

Phase Iii ◽

Phase Iii Trial ◽

Castration Resistant ◽

Hormone Sensitive ◽

Mature Analysis

223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

Annals of Oncology ◽

10.1016/j.annonc.2020.10.443 ◽

2020 ◽

Vol 31 ◽

pp. S1328

Author(s):

K. Fizazi ◽

N.D. Shore ◽

T.L.J. Tammela ◽

A. Ulys ◽

E. Vjaters ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Androgen Deprivation ◽

Phase Iii ◽

MP53-06 THE EFFECTIVE PERIOD OF FIRST ANDROGEN DEPRIVATION THERAPY BECOMES AN PROGNOSTIC THE EFFECTIVE PERIOD OF FIRST ANDROGEN-DEPRIVATION THERAPY BECOMES AN PROGNOSTIC FACTOR IN DOCETAXEL CHEMOTHERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER PATIENTS

The Journal of Urology ◽

10.1016/j.juro.2017.02.1657 ◽

2017 ◽

Vol 197 (4S) ◽

Author(s):

Keisuke Shigeta ◽

Takeo Kosaka ◽

Ryuichi MIzuno ◽

Toshiaki Shinojima ◽

Eiji KIkuchi ◽

...

Keyword(s):

Prostate Cancer ◽

Prognostic Factor ◽

Cancer Patients ◽

Androgen Deprivation ◽

Effective Period ◽

Castration Resistant ◽

Docetaxel Chemotherapy

Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration

International Journal of Clinical Oncology ◽

10.1007/s10147-019-01395-0 ◽

2019 ◽

Vol 24 (5) ◽

pp. 554-556

Author(s):

Keisuke Shigeta ◽

Takeo Kosaka ◽

Hiroshi Hongo ◽

Yoshinori Yanai ◽

Kazuhiro Matsumoto ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Clinical Benefit ◽

Poor Response ◽

Androgen Deprivation ◽

Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration

International Journal of Clinical Oncology ◽

10.1007/s10147-018-01388-5 ◽

2019 ◽

Vol 24 (5) ◽

pp. 546-553 ◽

Cited By ~ 1

Author(s):

Keisuke Shigeta ◽

Takeo Kosaka ◽

Hiroshi Hongo ◽

Yoshinori Yanai ◽

Kazuhiro Matsumoto ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Clinical Benefit ◽

Poor Response ◽

Androgen Deprivation ◽

Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy

Prostate International ◽

10.1016/j.prnil.2015.10.015 ◽

2015 ◽

Vol 3 (4) ◽

pp. 123-126 ◽

Cited By ~ 1

Author(s):

Minyong Kang ◽

Sangchul Lee ◽

Jong Jin Oh ◽

Sung Kyu Hong ◽

Sang Eun Lee ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Systemic Chemotherapy ◽

Androgen Deprivation ◽

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy

PLoS ONE ◽

10.1371/journal.pone.0229754 ◽

2020 ◽

Vol 15 (3) ◽

pp. e0229754

Author(s):

Zongwei Wang ◽

Tuo Deng ◽

Xingbo Long ◽

Xueming Lin ◽

Shulin Wu ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation ◽

Advanced age and early androgen deprivation therapy increase survival at different stages of the treatment in castration resistant prostate cancer patients

European Urology Open Science ◽

10.1016/s2666-1683(21)03147-5 ◽

2021 ◽

Vol 33 ◽

pp. S296

Author(s):

A.V. Ojeda Claro ◽

C.M. Fernández-Ávila ◽

M.F. Lorenzo Gómez ◽

M.J. Ledo Cepero ◽

E. Ruíz Guerrero ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation ◽

Advanced Age ◽

Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach

Asian Journal of Urology ◽

10.1016/j.ajur.2015.10.003 ◽

2016 ◽

Vol 3 (1) ◽

pp. 33-38 ◽

Cited By ~ 2

Author(s):

Kazuhiro Nagao ◽

Hideyasu Matsuyama ◽

Masahiro Nozawa ◽

Isao Hara ◽

Tsukasa Nishioka ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Cancer Patients ◽

Metastatic Prostate Cancer ◽

Androgen Deprivation ◽

Propensity Scoring ◽